A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer.
Latest Information Update: 29 Dec 2025
At a glance
- Drugs XH 001 (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
Most Recent Events
- 29 Dec 2025 New trial record